Treatment with aromatase inhibitors for breast cancer is associated with bone loss in postmenopausal women

被引：0
|
作者：
不详
机构：
来源：
Drugs & Therapy Perspectives | 2009年 / 25卷 / 10期
关键词：
D O I：
10.2165/0042310-200925100-00007
中图分类号：
学科分类号：
摘要：
Aromatase inhibitors are a component of the standard treatment of hormone receptor-positive breast cancer in postmenopausal women. However, their use is associated with accelerated bone loss and an increased rate of fractures, in what is already an at-risk population group. It is important to screen for and prevent aromatase inhibitor-associated bone los. © 2009 Adis Data Information BV. All rights reserved.
引用
收藏
页码：23 / 26
页数：3
相关论文
共 50 条
  • [41] Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis
    Hadji, Peyman
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2009, 69 (01) : 73 - 82
  • [42] Eldecalcitol Add-on to Risedronate Reduces Bone Loss From Aromatase Inhibitors in Postmenopausal Breast Cancer Patients
    Imanishi, Yasuo
    Imai, Takumi
    Fujii, Hisako
    Aida, Rei
    Nagata, Yuki
    Shoji, Tetsuo
    Kashiwagi, Shinichiro
    Takashima, Tsutomu
    Emoto, Masanori
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2025,
  • [43] Aromatase inhibitors in cancer treatment-induced bone loss
    Weilbaecher, KN
    JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 : P21 - P22
  • [44] In postmenopausal women with breast cancer treated with aromatase inhibitors, denosumab reduced fractures
    Wilcken, Nicholas
    Lee, Clara Inkyung
    ANNALS OF INTERNAL MEDICINE, 2015, 163 (06)
  • [45] The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women
    Mouridsen, HT
    Robert, NJ
    EUROPEAN JOURNAL OF CANCER, 2005, 41 (12) : 1678 - 1689
  • [46] Bone boss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies
    Coleman, Robert E.
    Body, Jean-Jacques
    Gralow, Julie R.
    Lipton, Allan
    CANCER TREATMENT REVIEWS, 2008, 34 : S31 - S42
  • [47] The use of aromatase inhibitors in postmenopausal women with hormone receptor positive breast cancer
    Benson, JR
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (27) : 6807 - 6809
  • [48] Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective
    Conte, PierFranco
    Frassoldati, Antonio
    BREAST JOURNAL, 2007, 13 (01): : 28 - 35
  • [49] TRABECULAR BONE SCORE IS PREDICTED BY PHALANGEAL QUANTITATIVE ULTRASOUND IN BREAST CANCER POSTMENOPAUSAL WOMEN RECEIVING AROMATASE INHIBITORS
    Catalano, A.
    Bellone, F.
    Agostino, R. M.
    Morabito, N.
    Gaudio, A.
    Lasco, A.
    OSTEOPOROSIS INTERNATIONAL, 2019, 30 : S549 - S549
  • [50] Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer
    Nogues, Xavier
    Servitja, Sonia
    Jesus Pena, Maria
    Prieto-Alhambra, Daniel
    Nadal, Rosa
    Mellibovsky, Leonardo
    Albanell, Joan
    Diez-Perez, Adolfo
    Tusquets, Ignasi
    MATURITAS, 2010, 66 (03) : 291 - 297
12345